Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 23, 2026

Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know

View original at finance.yahoo.com
Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know What Happened?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Until enterprise software companies prove AI revenue scales faster than it erodes the legacy subscription base, software stocks may remain in the penalty box even on days when chip stocks rally

    60% confidence
  • Salesforce is a Buy on valuation grounds

    60% confidence
  • Salesforce is a Rule-of-40 company retiring 10% of its shares through a $25 billion buyback

    60% confidence
  • AI agents will erode the subscription model that underpins traditional enterprise software economics

    60% confidence
  • The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks

    60% confidence
  • If the largest IT services firm in the world signals AI is eating its billable hours, investors will extend the same logic to software vendors whose products those hours configure

    60% confidence
  • Salesforce is acquiring m3ter to monetize AI agent actions rather than per-seat subscriptions

    60% confidence
  • The software sell-off has become indiscriminate; the market is pricing AI cannibalization as if it already happened while income statements may be indicating otherwise

    60% confidence
  • AI is compressing demand for traditional IT services

    60% confidence
  • Salesforce carries the largest AI revenue line in the enterprise software category

    60% confidence

Data points we hold from this source

Salesforce · stock price152 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know — Source | Via News | Finance Via News